Because cisplatin‐based chemotherapy mainly induces double‐strand breaks and apoptosis in tumour cells, suppressing the ZBTB11/DDX1 signalling axis may increase the cisplatin sensitivity of BC cells. This evidence concerns the gene DDX1 and breast cancer.